Advertisement
Home 2017

Archives

Social jet lag, a mismatch between the body's biological clock and actual sleep pattern due to social activities is associated with adverse health effects

SLEEP: Weekend Sleep Changes Adversely Affect Health Outcomes

0
For every hour of shifted sleep, an associated 11.1 percent increase in risk of diagnosed heart disease
Prolonged delayed eating is associated with weight gain and increases in respiratory quotient

SLEEP: Prolonged Delayed Eating Linked to Weight Gain

0
Compared with daytime eating, delayed eating also linked to increases in respiratory quotient
Social jet lag, a mismatch between the body's biological clock and actual sleep pattern due to social activities is associated with adverse health effects

APSS: Weekend Sleep Changes Adversely Affect Health Outcomes

0
For every hour of shifted sleep, an associated 11.1 percent increase in risk of diagnosed heart disease
There is little agreement between the American Society of Clinical Oncology Value Framework and European Society for Medical Oncology Magnitude of Clinical Benefit Scale

ASCO: Agreement Lacking With ESMO on Most Effective Drugs

0
Negative correlation identified for ASCO benefit score with monthly incremental drug costs
From 2013 to 2015 there was a decrease in additional surgery after initial lumpectomy

ASCO: Recent Drop in Additional Surgery Post Lumpectomy

0
Decrease was concomitant with 2014 consensus statement endorsing a margin of no ink on tumor
Two new medications that target specific genetic mutations may improve survival for patients with specific types of advanced non-small-cell lung cancer

ASCO: Novel Meds Show Promise in Advanced NSCLC

0
Results presented from two phase III trials
A new type of immunotherapy appears to provide long-lasting protection against multiple myeloma

ASCO: CAR T-Cell Therapy Promising in Multiple Myeloma

0
Findings from trial of chimeric antigen receptor T cells targeting B-cell maturation protein
Over the past 60 years

ASCO: SWOG Trials Have Had Considerable Impact on Cancer

0
Estimated 3.34 million life-years gained through 2015 from 23 positive SWOG treatment trials
Free meals

ASCO: Industry Perks Influence Physicians’ Choice of Cancer Rx

0
Even relatively small payments appear to make a difference, researchers say
Olaparib (Lynparza) monotherapy can provide a significant benefit over standard therapy in women with human epidermal growth factor receptor type 2-negative metastatic breast cancer and a germline BRCA mutation

ASCO: Olaparib Efficacious in BRCA-Related Breast Cancer

0
May offer a new treatment for women with advanced BRCA-related disease, researchers say